Full-Time

Equipment Engineer I

Posted on 8/28/2024

Adaptive Biotechnologies

Adaptive Biotechnologies

501-1,000 employees

Decodes immune cell genetic information for diagnostics

Compensation Overview

$79.4k - $119.2kAnnually

+ Equity Grant + Bonus Eligible

Entry, Junior

No H1B Sponsorship

Seattle, WA, USA

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Communications
Management
Requirements
  • Associate in engineering or science, 4+ yrs. related experience
  • Bachelors in engineering or science, 2+ yrs. related experience
  • Ability to author Standard Operation Procedures (SOPs), equipment and method IQOQ plans and reports, and Change Control Requests (CCRs) and Design Input Requirements (DIRs)
  • Solid customer-first communication skills as a team representative
  • Experience working with commercial off-the-shelf benchtop lab equipment and automated liquid handling platforms (e.g., Hamilton, Tecan, Dynamic Devices, Formulatrix)
  • Ability to troubleshoot and solve engineering problems with structured approaches and suggest improvements (e.g. application of first principles, Lean Six Sigma)
  • Experience gathering and reporting metrics.
Responsibilities
  • Performs the installation and operational qualification (IOQ) for standard lab equipment (e.g., handheld pipettes, thermocyclers, centrifuges, plate readers, tube pickers, tube capper/decapper), controlled temperature units (e.g. refrigerators and freezers), environmental monitoring system (e.g., Vaisala)
  • Coordinates the preventative maintenance and calibration of complex lab equipment (e.g., liquid handlers, sequencers)
  • Supports Equipment Lifecycle Management processes and procedures by supporting and maintaining equipment records for traceability purposes
  • Assists in troubleshooting and incident management of a subset of lab equipment.
  • Supports vendor services and facilities' system management.
  • Performs preventative maintenance and calibration of complex lab equipment (e.g., liquid handlers, sequencers)
  • Supports hardware and software integrations with software platforms (e.g., LIMS, log management services, schedulers, orchestrators, etc.) with lab equipment (e.g., liquid handlers)
  • Participates in equipment and automation development lifecycles, with developing emphasis on specific lifecycle phases.
  • Drives ideation and implements continuous improvement ideas for relevant business and laboratory process step(s)
  • Coordinates routine maintenance and calibration of lab and facility equipment with external vendors and suppliers.
  • Prepares and reviews documents (e.g., protocols, reports, nonconformances, risk assessments, change control requests) to ensure compliance in Quality environment.
  • May support internal and external audits with review of equipment records and related procedures.
  • Trains end users and teammates with a customer-first mindset
Adaptive Biotechnologies

Adaptive Biotechnologies

View

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand how the immune system reacts to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to advance healthcare by leveraging immune system data to develop better therapies and diagnostic tools.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$395.8M

Headquarters

Seattle, Washington

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • Strong investor confidence with investments from firms like Jacobs Levy and Acadian Asset Management.
  • Partnership with EndoSound could expand product offerings in the medical device market.
  • Recognition as Workplace of the Year highlights a strong company culture attracting top talent.

What critics are saying

  • Emerging competition from startups like Adaptive with $20 million funding for AI applications.
  • Regulatory hurdles in developing new medical devices with EndoSound partnership.
  • Pressure from investors for rapid financial returns may impact long-term R&D.

What makes Adaptive Biotechnologies unique

  • Adaptive Biotechnologies leverages immune system data for disease diagnosis and treatment.
  • Their clonoSEQ test is FDA-authorized for monitoring minimal residual disease in blood cancers.
  • The ImmuneRACE study enhances understanding of immune responses to COVID-19.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

2%
GlobeNewswire
Jan 2nd, 2025
Adaptive Biotechnologies To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.About Adaptive BiotechnologiesAdaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease

MarketBeat
Dec 10th, 2024
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Jacobs Levy Equity Management Inc. makes new $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).

Adaptive Biotechnologies
Dec 3rd, 2024
Press Release Details

"We are inspired to see clonoSEQ MRD testing featured in a record-breaking number of studies at this year's ASH Annual Meeting," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies.

ETF Daily News
Sep 29th, 2024
Canada Pension Plan Investment Board Makes New $98,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Canada Pension Plan Investment Board makes new $98,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).

MarketBeat
Jul 28th, 2024
Acadian Asset Management LLC Invests $519,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Acadian Asset Management LLC invests $519,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT).

INACTIVE